Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 15, Issue 3-4, 2014, Pages 285-291

  Jones, Ashley R ^a   Jivraj, Naheed ^a   Balendra, Rubika ^a   Murphy, Caroline ^b   Kelly, Joanna ^b   Thornhill, Marie ^b   Young, Carolyn ^c   Shaw, Pamela J ^d   Leigh, P Nigel ^a,e   Turner, Martin R ^f   Steen, I Nick ^g   Mccrone, Paul ^a   Al Chalabi, Ammar ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF SUSSEX   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Clinical staging; EQ 5D; Health utility; Quality of life

Indexed keywords

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; EMOTION; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; KING AMYOTROPHIC LATERAL SCLEROSIS STAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGED; CLINICAL TRIAL; COMPLICATION; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; ECONOMICS; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PSYCHOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; COST-BENEFIT ANALYSIS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84901494031     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.872149     Document Type: Article

References (28)

1. Talbot K. Motor neuron disease: The bare essentials. Pract Neurol. 2009;9:303-9
2. Veldink JH, Wokke JHJ, van der Wal G, Vianney de Jong JMB, van den Berg LH. Euthanasia and Physician-Assisted Suicide among Patients with Amyotrophic Lateral Sclerosis in the Netherlands. N Engl J Med. 2002;346:1638-44
3. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: A population based study of inner city London. J Neurol. 2006;253:1642-3. (Pubitemid 46116727
4. Zinman L, Cudkowicz M. E merging targets and treatments in amyotrophic lateral sclerosis. The Lancet Neurol. 2011;10:481-90
5. NICE. G uide to the methods of technology appraisal. 2008; June
6. EuroQol. E uroQol-A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208
7. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847-52
8. W inter Y, Schepelmann K, Spottke A, Claus D, Grothe C, Schr ö der R, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257:1473-81
9. UKMND-LiCALS GS. L ithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339-45
10. Al-Chalabi A, Shaw P, Young C, Morrison K, Murphy C, Thornhill M, et al. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic Lateral Sclerosis (LiCALS) [Eudract number: 2008-006891-31]. BMC Neurol. 2011;11:111
11. Dolan P, Stalmeier P. The validity of time trade-off values in calculating QALYs: Constant proportional time trade-off versus the proportional heuristic. J Health Econ. 2003;22:445-58. (Pubitemid 36390315
12. Greiner W, Claes C, Busschbach J JV, Schulenburg J M. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6:124-30. (Pubitemid 40905009
13. Dolan P. Modelling valuations for health states: The effect of duration. Health policy. 1996;38:189-203. (Pubitemid 26338161
14. Gibbons C, Mills R, Thornton E, Ealing J, Mitchell J, Shaw P, et al. Rasch analysis of the Hospital Anxiety and Depression Scale (HADS) for use in motor neurone disease Health Qual Life Outcomes. 2011;9:82
15. Kiebert GM, Green C, Murphy C, Mitchell JD, O 'Brien M, Burrell A, et al. Patients ' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci. 2001;191:87-93
16. Norquist JM, Jenkinson C, Fitzpatrick R, Swash M. Factors which predict physical and mental health status in patients with amyotrophic lateral sclerosis over time. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:112-7. (Pubitemid 36874781
17. Chiò A, Gauthier A, Montuschi A, Calvo A, D i Vito N, Ghiglione P, et al. A cross sectional study on determinants of quality of life in ALS. J Neurol Neurosurg Psychiatry. 2004;75:1597-601. (Pubitemid 39430613
18. Jenkinson C, Fitzpatrick R, Swash M, Peto V. The ALS Health Profi le Study: Quality of life of amyotrophic lateral sclerosis patients and carers in Europe. J Neurol. 2000;247:835-40
19. De Groot IJM, Post MWM, Heuveln Tv, Van den Berg LH, Lindeman E. Cross-sectional and longitudinal correlations between disease progression and different health-related quality of life domains in persons with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8:356-61
20. Averill A, Kasarskis E, Segerstrom S. P sychological health in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8:243-54. (Pubitemid 47190229
21. Dolan P. U sing Happiness to Value Health. London, UK: Offi ce of Health Economics. 2011 (Report No. 1
22. Jensen MP, Abresch RT, Carter GT, McDonald C M. Chronic Pain in Persons With Neuromuscular Disease. Arch Phys Med Rehabil. 2005;86:1155-63. (Pubitemid 40797769
23. B ehari M, Srivastava AK, Pandey RM. Q uality of life in patients with Parkinson's disease. Parkinsonism Relat Disord. 2005;11:221-6
24. Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker R A. Health-related quality of life in Huntington's disease: Which factors matter most?. Mov Disord. 2009;24:574-8
25. Oh H, Sin M-K, Schepp KG, Choi-Kwon S. D epressive Symptoms and Functional Impairment Among Amyotrophic Lateral Sclerosis Patients in South Korea. Rehabil Nurs. 2012;37:136-44
26. R abkin JG, Wagner GJ, Del Bene M. R esilience and Distress Among Amyotrophic Lateral Sclerosis Patients and Caregivers. Psychosom Med. 2000;62:271-9
27. Lillo P, Mioshi E, Zoing MC, Kiernan MC, Hodges J R. How common are behavioural changes in amyotrophic lateral sclerosis?. Amyotroph Lateral Scler. 2011;12:45-51
28. Mendez MF, Perryman KM. N europsychiatric Features of Frontotemporal DementiaEvaluation of Consensus Criteria and Review. J Neuropsychiatry Clin Neurosci. 2002;14:424-9. (Pubitemid 35265989.